CRON
Cronos GroupCRON
CRON
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
104% more call options, than puts
Call options by funds: $8.36M | Put options by funds: $4.1M
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
3% more funds holding
Funds holding: 176 [Q3] → 182 (+6) [Q4]
0.47% more ownership
Funds ownership: 10.89% [Q3] → 11.35% (+0.47%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
4% less capital invested
Capital invested by funds: $91.3M [Q3] → $87.6M (-$3.76M) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
Research analyst outlook
We haven’t received any recent analyst ratings for CRON.
Financial journalist opinion
Based on 9 articles about CRON published over the past 30 days
Positive
MarijuanaStocks
2 days ago
Top Canadian Cannabis Stocks to Watch in April 2025
Top Canadian cannabis stocks are attracting attention this week as investors seek opportunities in a rapidly evolving industry. Companies like Cronos Group, SNDL Inc., and Aurora Cannabis continue strengthening their positions in Canadian and international markets. Though based in Canada, these firms have exposure to the U.S. through strategic investments and partnerships. The U.S. cannabis industry is expected to generate over $45 billion annually by 2025. Legalization efforts are expanding, and several states are reviewing new adult-use and medical cannabis bills. At the same time, court rulings and state-level decisions continue to shape the legal landscape. Because of this, Canadian companies with U.S. exposure are drawing increased interest from traders and long-term investors alike.
Positive
Finbold
4 days ago
Cronos (CRO) soars 31% since Trump teamed up with Crypto.com
The week that started on Monday, March 24, has been bloody in the equity markets and, by Friday, March 28, ensured that cryptocurrencies have also joined the plunge with a $100 billion 24-hour valuation drop.
Positive
Seeking Alpha
1 week ago
Cronos Stock: Win Big Or Lose All
I maintain a 'strong buy' rating for Cronos, despite regulatory headwinds, due to its strong fundamentals and potential for multibagger returns. Cronos has shown positive progress with a robust cash buffer, 35% revenue growth, reduced EBITDA losses, and positive operating cash flows in FY 2024. International expansion, strategic investments, and a focus on R&D are key drivers for Cronos' sustained top-line growth and market diversification.
Neutral
MarijuanaStocks
1 week ago
3 Canadian Marijuana Stocks To Watch For Future Gains 2025
Marijuana stocks have been facing a downward trend in the market for some time. A big reason is regulatory uncertainty and reform issues. Legislative changes, particularly in major markets like the U.S., can greatly affect how shareholders think. Additionally, oversupply in certain regions has led to falling prices, which negatively affects revenue for companies in the sector. This has created a volatile sector where the trading behavior of the most public companies is more on the low end.
Neutral
GlobeNewsWire
1 week ago
Cronos Appoints Anna Shlimak as Chief Financial Officer
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition.
Neutral
Seeking Alpha
2 weeks ago
Cronos Group Inc. (CRON) 37th Annual Roth Conference (Transcript)
Cronos Group Inc. (NASDAQ:CRON ) 37th Annual Roth Conference March 17, 2025 4:00 PM ET Company Participants Mike Gorenstein - Chairman, President and Chief Executive Officer Conference Call Participants Bill Kirk - Roth Capital Partners Bill Kirk Awesome. Good afternoon everybody.
Neutral
GlobeNewsWire
3 weeks ago
Cronos Group Inc. to Speak at the 37th Annual Roth Conference
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 37th Annual Roth Conference on Monday, March 17, 2025, at 1:00 PM PT.
Positive
Seeking Alpha
3 weeks ago
Cronos Reports Improved Q4-2024 Financials With Revenues From GrowCo
Cronos reported 27% increase in revenues YOY for Q4-2024. The company is now reporting revenues from its 50% ownership of GrowCo. The company reported increasing profits and free cash flow for the quarter.
Positive
MarijuanaStocks
3 weeks ago
Top Marijuana Stocks To Know In Today's Stock Market 2025
As the cannabis industry continues to grow, more companies are expanding their product lines beyond traditional flower sales. This includes edibles, oils, and wellness products, attracting a broader consumer base. The demand for more cannabis products is helping bridge some gaps between existing players. For example, when companies partner in some way to create and release products, it often has a positive impact all the way around for the companies.
Positive
Benzinga
1 month ago
Cronos Q4 Sales Jump 27% On Higher Cannabis Flower And Extract Sales, Reports Improved Profitability
On Thursday, Cronos Group Inc CRON reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.
Charts implemented using Lightweight Charts™